NCT01267968View on ClinicalTrials.gov

An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 11, 2011

Primary Completion Date

March 16, 2011

Study Completion Date

March 16, 2011

Conditions
Community-acquired Infection
Interventions
DRUG

GSK2251052

1500 mg (dosing detailed in Arm description)

Trial Locations (1)

55404

GSK Investigational Site, Minneapolis

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01267968 - An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter